Page 5 - Sedesa Pointed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sedesa pointed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sedesa Pointed Today - Breaking & Trending Today

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone


Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company s drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis (ACD), a potentially debilitating condition and occupational illness.
Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa s EB01 topical treatment or a placebo cream. EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Since EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety ....

United States , United Kingdom , Gary Koppenjan , Exchange Commission , Edesa Biotech Inc , British Columbia Securities Commission , Drug Administration , Securities Exchange , Edesa Biotech , Allergic Contact Dermatitis , Par Nijhawan , Chief Executive Officer , Acute Respiratory Distress Syndrome , Securities Act , Securities Exchange Act , British Columbia Securities , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பரிமாற்றம் தரகு , பிரிட்டிஷ் கொலம்பியா பத்திரங்கள் தரகு , பத்திரங்கள் பரிமாற்றம் , இணையானது நிஜவன் , தலைமை நிர்வாகி அதிகாரி , எடுப்போசை சுவாச துன்பம் நோய்க்குறி , பத்திரங்கள் நாடகம் , பத்திரங்கள் பரிமாற்றம் நாடகம் ,

Edesa Biotech Reports Fiscal First Quarter 2021 Results


Edesa Biotech Reports Fiscal First Quarter 2021 Results
TORONTO, ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2020 and provided an update on its business.
Earlier this month, the company announced that it has been awarded a C$14 million reimbursement grant from the Canadian government. The funds will support the Phase 2 portion of an ongoing Phase 2/Phase 3 clinical study of Edesa s investigational drug, EB05, as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Should the antibody treatment demonstrate promising results at the Phase 2 readout, the company plans to continue with a pivotal Phase 3 study and enter negotiations for additional government funding. ....

United States , United Kingdom , Kathi Niffenegger , Gary Koppenjan , Exchange Commission , Edesa Biotech Inc , British Columbia Securities Commission , Drug Administration , Securities Exchange , Health Canada , Edesa Biotech , Acute Respiratory Distress Syndrome , Par Nijhawan , Chief Executive Officer , Chief Financial Officer Kathi Niffenegger , Three Months Ended December , Annual Global Life Sciences Conference , Securities Act , Securities Exchange Act , British Columbia Securities , Interim Consolidated Statements , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பரிமாற்றம் தரகு , பிரிட்டிஷ் கொலம்பியா பத்திரங்கள் தரகு , பத்திரங்கள் பரிமாற்றம் ,